Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure.
about
Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivoInhibition of cyclo-oxygenase-2 exacerbates ischaemia-induced acute myocardial dysfunction in the rabbitDiscovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioningMyotrophin/V-1, a protein up-regulated in the failing human heart and in postnatal cerebellum, converts NFkappa B p50-p65 heterodimers to p50-p50 and p65-p65 homodimersExpression and activity of cyclooxygenase isoforms in skeletal muscles and myocardium of humans and rodentsNuclear co-translocation of myotrophin and p65 stimulates myocyte growth. Regulation by myotrophin hairpin loopsDownregulation of NADPH oxidase, antioxidant enzymes, and inflammatory markers in the heart of streptozotocin-induced diabetic rats by N-acetyl-L-cysteineSeptic cardiomyopathy - A not yet discovered cardiomyopathy?Dichotomous actions of NF-kappaB signaling pathways in heart.Nuclear Factor (NF) kappaB polymorphism is associated with heart function in patients with heart failure.Regulation of heat shock protein 60 and 72 expression in the failing heart.Basic biology and clinical application of specific cyclooxygenase-2 inhibitors.Preserved heart function and maintained response to cardiac stresses in a genetic model of cardiomyocyte-targeted deficiency of cyclooxygenase-2.Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study.Increased expression of integrin-linked kinase improves cardiac function and decreases mortality in dilated cardiomyopathy model of rats.MicroRNA-301a mediated regulation of Kv4.2 in diabetes: identification of key modulators.Efficacy of female rat models in translational cardiovascular aging researchThe use of moderate hypothermia during cardiac surgery is associated with repression of tumour necrosis factor-alpha via inhibition of activating protein-1: an experimental studyPrevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors.Gene expression network analysis reveals new transcriptional regulators as novel factors in human ischemic cardiomyopathyLeft ventricular diastolic function associated with common genetic variation in ATP12A in a general population.Cyclo-oxygenase-2 (COX-2) expression at the site of recent myocardial infarction: friend or foe?Left ventricular remodeling in swine after myocardial infarction: a transcriptional genomics approach.Infiltration of inflammatory cells plays an important role in matrix metalloproteinase expression and activation in the heart during sepsis.Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and managementAngiotensin-(1-7) abrogates mitogen-stimulated proliferation of cardiac fibroblasts.Low-grade inflammation and the phenotypic expression of myocardial fibrosis in hypertrophic cardiomyopathy.Activation of nuclear factor-kappaB is necessary for myotrophin-induced cardiac hypertrophy.Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Prevention of cardiac hypertrophy and heart failure by silencing of NF-kappaB.Muscle cyclo-oxygenase-2 pathway contributes to the exaggerated muscle mechanoreflex in rats with congestive heart failure.Modulation of prostaglandin activity, part 1: prostaglandin inhibition in the management of nonrheumatologic diseases: immunologic and hematologic aspects.Hyperoxia-induced hypertrophy and ion channel remodeling in left ventricleCorticosteroids induce COX-2 expression in cardiomyocytes: role of glucocorticoid receptor and C/EBP-betaSelective cyclooxygenase-2 inhibition protects against myocardial damage in experimental acute ischemiaRole of peroxynitrite in the redox regulation of cell signal transduction pathwaysEicosanoid signalling pathways in the heart.Blockade of NF-kappaB using IkappaB alpha dominant-negative mice ameliorates cardiac hypertrophy in myotrophin-overexpressed transgenic mice.Feed-forward signaling of TNF-alpha and NF-kappaB via IKK-beta pathway contributes to insulin resistance and coronary arteriolar dysfunction in type 2 diabetic miceSilencing the myotrophin gene by RNA interference leads to the regression of cardiac hypertrophy.
P2860
Q28188254-742F974F-CAA7-40B4-9701-51E46A0C53E0Q28192589-D8606E86-7680-42D6-B828-A73AC72BCF9EQ28193545-033C92B1-604B-424C-A1A3-9FA9474A2282Q28215631-0078FD47-FF4D-4756-85F2-0FD4DD19DCC9Q28575889-7F74F700-FB12-4394-8F71-61228B056E9AQ28580293-3FB2C1C0-70D5-4DF2-918C-4F6E108C9FCFQ28582183-09B5A38E-0F93-40CC-87F7-859502755DB6Q30319484-0C05997B-D0DB-4C25-BA37-EB0AF8105F54Q30390478-BAF10820-8EB5-4124-B9D0-B26EFAB18AEEQ33599397-2422B7F5-8CBB-451E-930B-6009BFF8E258Q33621507-B89C12E3-373B-49B2-BB9A-79726ED9418FQ33822140-267883CD-E18E-4ED2-89B1-BA9583B7D7B2Q33937192-27B5D829-A6E4-45B5-9DFC-81820AA06713Q33941101-3CF649FA-70F3-47C6-A21F-0C1201E24985Q34163462-ADBDEF05-CBF6-4513-97F2-25C58E4FF0FCQ34662020-2C2375ED-890B-4C3E-A4DA-60486168E39DQ34958259-FEFB0A68-5D40-4CBC-9253-FD0C7D722470Q34999428-6C9E924F-6236-45A6-89F8-8B3CC9971A73Q35214761-D39630A7-10BF-489B-9E6C-37F519DA24D3Q35276352-C30EC623-28BA-4B56-B87B-9665AB4C0A90Q35388910-5C0FFAAC-77DA-4652-A663-E0A27ED5C69EQ35582181-7BAC59AC-062C-4211-B43C-278461B95C4AQ35587392-B27A5DE3-D5EE-4579-8FDB-1AF0C32C3443Q35607377-DD2796A2-51D4-4557-B3C4-A105FA91A808Q35868495-13D3A576-D43D-4B2B-BB15-39119A0941AFQ35889735-B355ED45-EF38-48C6-B1EF-4AE767FCAE18Q36011990-54BCAF63-DF69-4EF2-AD66-870F038B322FQ36325539-AF8D89DC-1A19-40A5-83E4-EA8F5C071872Q36439704-FAE05C35-DE90-4B9D-BBED-6A5467EF98FBQ36514490-18CD0D8E-DC58-4430-8AC3-D0578DBC457CQ36710218-A9F8ABE6-A925-45CE-8BC1-BB0C4DC64B88Q36831852-F6CF43AB-E7C1-4C5B-9630-62D5E563D769Q36923943-E27A9758-004B-416C-BEFF-705332C22498Q36955826-4711FFE6-26A3-4D71-8699-38AD234ACF83Q37152580-EA8286CD-3F69-44A8-B9F8-BC9127F590FEQ37159262-1BB43A2E-EAC6-4AF1-B024-FC2B4F7D24F0Q37176175-F2798592-E4A3-4161-8D77-FAD100FAA387Q37208204-9544E1AA-5417-4343-A0F3-FB9200DCED31Q37276227-17EFD61B-7043-4B6D-BC0D-6DD1BEF3EAE5Q37298305-E5203345-4822-4CF5-9C14-2987DD2AA6BF
P2860
Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Induction of cyclooxygenase-2 ...... with congestive heart failure.
@en
Induction of cyclooxygenase-2 ...... with congestive heart failure.
@nl
type
label
Induction of cyclooxygenase-2 ...... with congestive heart failure.
@en
Induction of cyclooxygenase-2 ...... with congestive heart failure.
@nl
prefLabel
Induction of cyclooxygenase-2 ...... with congestive heart failure.
@en
Induction of cyclooxygenase-2 ...... with congestive heart failure.
@nl
P2093
P356
P1433
P1476
Induction of cyclooxygenase-2 ...... with congestive heart failure.
@en
P2093
P304
P356
10.1161/01.CIR.98.2.100
P407
P577
1998-07-01T00:00:00Z